EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types

被引：0

作者：

Huageng Huang

Xinyi Deng

Le Yu

He Huang

Zhao Wang

Huangming Hong

Tongyu Lin

机构：

[1] Sun Yat-Sen University Cancer Center,Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer

[2] The First Affiliated Hospital of Guangzhou Medical University,Department of Dermatology

[3] University of Electronic Science and Technology of China,Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine

来源：

Journal of Translational Medicine | / 21卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 28 条

[1]

Sharma P(2023)Immune checkpoint therapy-current perspectives and future directions Cell 186 1652-1669

[2]

Goswami S(2023)Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade Drug Resist Updat 66 6075-6080

[3]

Raychaudhuri D(2019)EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer Proc Natl Acad Sci USA 116 517-528

[4]

Pang K(2019)EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains Nat Genet 51 5449-5458

[5]

Shi ZD(2020)EZH2-targeted therapies in cancer: hype or a reality Cancer Res 80 948-963

[6]

Wei LY(2020)Overcoming immune checkpoint blockade resistance via EZH2 inhibition Trends Immunol 41 723-733

[7]

Wassef M(2020)Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses Acta Pharm Sin B 10 151-161

[8]

Luscan A(2023)Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study Lancet Oncol 24 4-17

[9]

Aflaki S(2022)Predictive biomarkers for response to immune checkpoint inhibition Semin Cancer Biol 79 undefined-undefined

[10]

Donaldson-Collier MC(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 →